WO/2015/107444 IN-VITRO ASSAY FOR THE ASSESSMENT OF POST TRANSLATIONALLY MODIFIED PROTEIN ISOFORMS||WO||23.07.2015|
||PCT/IB2015/050212||DR.REDDYS LABORATORIES LIMITED||MEDISETTY, Rajesh|
The present invention discloses an in-vitro bioassay for distinguishing post translationally modified isoforms of a protein. In particular, the present invention discloses an in-vitro method for distinguishing post translationally modified isoforms of an antibody by C1q based ELISA involving a metal ion chelator.
WO/2015/059679 IMPROVED PROCESS FOR THE PREPARATION OF ELIGLUSTAT||WO||30.04.2015|
||PCT/IB2014/065631||DR. REDDY'S LABORATORIES LIMITED||JAVED, Iqbal|
The present invention provides an improved process for the preparation of eliglustat to salts thereof. Present invention also provides a crystalline eliglustat free base form R1.
WO/2015/044876 MOLECULAR WEIGHT MARKERS FOR PROTECTED POLYPEPTIDES||WO||02.04.2015|
||PCT/IB2014/064797||DR. REDDY'S LABORATORIES LIMITED||KATKAM, Srinivas|
The present invention provides trifluoroacetyl copolymers useful as standard molecular weight markers in the intermediary stage for obtaining glatiramer acetate having desired average molecular weight. The present invention further provides a process for determining the average molecular weight of glatiramer acetate or other copolymers using molecular weight markers of protected polypeptides.
WO/2015/026737 SELECTABLE SINGLE DOSE AUTO-INJECTOR AND METHODS OF MAKING AND USING SAME||WO||26.02.2015|
||PCT/US2014/051531||DR. REDDY'S LABORATORIES, LTD.||KUMAR, Rajesh|
An auto-injector device for administering a liquid pharmaceutical composition, in which an end-user can select between doses that the device is capable of delivering. The end-user choices that translate into the selected doses can be based on end-user perceived severity of symptoms, end-user weight and other such factors. In some embodiments the auto-injector is configured to administer the one chosen dose only. In other embodiments, the auto-injector can deliver second and subsequent doses up to full dose of the pharmaceutical composition disposed in the injector. The auto-injector can provide visual, audio, and tactile feedback, alone or in combination, to the user to indicate the dose selected, instructions for use, and when the dose has been administered.
WO/2014/188353 PROCESSES FOR THE PREPARATION OF DEHYDROEPIANDROSTERONE AND ITS INTERMEDIATES||WO||27.11.2014|
||PCT/IB2014/061590||DR. REDDY'S LABORATORIES LIMITED||FRYSZKOWSKA, Anna|
The present application relates to a regioselective and stereoselective processes for the preparation of dehydroepiandrosterone (DHEA) and processes for its intermediates.
WO/2014/170866 PROCESS OF OBTAINING GLYCOPROTEIN COMPOSITION WITH INCREASED GALACTOSYLATION CONTENT||WO||23.10.2014|
||PCT/IB2014/060812||DR. REDDY'S LABORATORIES LIMITED||THUDUPPATHY, Guruvasuthevan Ramasamy|
A cell culture process for production of glycoprotein composition with increased galactosylation content while maintaining specific productivity is provided. The process involves culturing cells at high pCO 2 and subjecting cells to temperature downshift to obtain a glycoprotein with specific glycoprotein composition.
WO/2014/155349 REFOLDING OF PROTEINS||WO||02.10.2014|
||PCT/IB2014/060251||DR. REDDY'S LABORATORIES||PARAYITAM, Bharata, Ratnam|
Provided is a method of refolding of recombinant GCSF that minimizes the generation of oxidized forms of GCSF by optimizing the refolding of inclusion bodies containing recombinant GCSF.
WO/2014/145710 PARENTERAL DICLOFENAC COMPOSITION||WO||18.09.2014|
||PCT/US2014/030519||DR. REDDY'S LABORATORIES, LTD.||OKUMU, Franklin|
The present application provides parenteral compositions of diclofenac or its pharmaceutically acceptable salt and methods for making and using such compositions. Some of the compositions of the present application has one or more following properties: (1) ready to be injectable, (2) in the form of an oil-in-water emulsion, (3) stable under appropriate storage conditions, (4) containing therapeutically effective amount of diclofenac or its pharmaceutically acceptable salt, (5) sterilizable by filtration (6) containing components acceptable by regulatory agencies (e.g. the FDA), (7) containing low oil content and thus not exacerbating hyerlipidemia, and (8) is neither hyperallergenic nor vein irritating.
WO/2014/128564 PHARMACEUTICAL COMPOSITIONS OF CETP INHIBITORS||WO||28.08.2014|
||PCT/IB2014/000715||DR. REDDY'S LABORATORIES LTD.||NEKKANTI, Vijay, Kumar|
The present application discloses a pharmaceutical composition comprising a class of cholesteryl ester transfer protein (CETP) inhibitors with improved oral bioavailability. The application further discloses compositions comprising a class of CETP inhibitor and at least one surfactant in the form of a solution, suspension, emulsion or a pre-concentrate.
WO/2014/118685 METHOD OF ALTERING THE ACIDIC VARIANT CONTENT OF ANTIBODY||WO||07.08.2014|
||PCT/IB2014/058553||DR. REDDY'S LABORATORIES LIMITED||KULKARNI, Samir, R.|
A method of altering the amount of acidic variants in antibody composition, in particular, employs a cation exchange chromatography with varying amounts of wash buffer column volume to alter the acidic variant content of the antibody.